Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients.

Smedman TM, Line PD, Guren TK, Dueland S.

Acta Oncol. 2018 Jun 18:1-5. doi: 10.1080/0284186X.2018.1479069. [Epub ahead of print] No abstract available.

PMID:
29912605
2.

Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer.

Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR, Nielsen DL, Ree AH.

Br J Cancer. 2018 May;118(10):1322-1328. doi: 10.1038/s41416-018-0085-y. Epub 2018 Apr 26.

PMID:
29695770
3.

Beyond total mesorectal excision in locally advanced rectal cancer with organ or pelvic side-wall involvement.

Mariathasan AB, Boye K, Giercksky KE, Brennhovd B, Gullestad HP, Emblemsvåg HL, Grøholt KK, Dueland S, Flatmark K, Larsen SG.

Eur J Surg Oncol. 2018 Aug;44(8):1226-1232. doi: 10.1016/j.ejso.2018.03.029. Epub 2018 Apr 12.

PMID:
29691115
4.

Importance of 18F-FDG PET/CT to select patients with nonresectable colorectal liver metastases for liver transplantation.

Grut H, Revheim ME, Line PD, Dueland S.

Nucl Med Commun. 2018 Jul;39(7):621-627. doi: 10.1097/MNM.0000000000000843.

PMID:
29683930
5.

The Potential Role of Liver Transplantation as a Treatment Option in Colorectal Liver Metastases.

Line PD, Hagness M, Dueland S.

Can J Gastroenterol Hepatol. 2018 Jan 17;2018:8547940. doi: 10.1155/2018/8547940. eCollection 2018. Review.

6.

Survival following liver transplantation for liver-only colorectal metastases compared with hepatocellular carcinoma.

Dueland S, Foss A, Solheim JM, Hagness M, Line PD.

Br J Surg. 2018 May;105(6):736-742. doi: 10.1002/bjs.10769. Epub 2018 Mar 13.

PMID:
29532908
7.

Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases.

Grut H, Solberg S, Seierstad T, Revheim ME, Egge TS, Larsen SG, Line PD, Dueland S.

Br J Surg. 2018 Feb;105(3):295-301. doi: 10.1002/bjs.10651. Epub 2017 Nov 23.

PMID:
29168565
8.

The prognostic value of 18F-FDG PET/CT prior to liver transplantation for nonresectable colorectal liver metastases.

Grut H, Dueland S, Line PD, Revheim ME.

Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):218-225. doi: 10.1007/s00259-017-3843-9. Epub 2017 Oct 12.

PMID:
29026950
9.

Acute liver graft rejection after ipilimumab therapy.

Dueland S, Guren TK, Boberg KM, Reims HM, Grzyb K, Aamdal S, Julsrud L, Line PD.

Ann Oncol. 2017 Oct 1;28(10):2619-2620. doi: 10.1093/annonc/mdx281. No abstract available.

PMID:
28961840
10.

Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.

Labori KJ, Lassen K, Hoem D, Grønbech JE, Søreide JA, Mortensen K, Smaaland R, Sorbye H, Verbeke C, Dueland S.

BMC Surg. 2017 Aug 25;17(1):94. doi: 10.1186/s12893-017-0291-1.

11.

Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate.

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA, Hagene KT, Aas E, Lurås H, Johnsen-Soriano S, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Mælandsmo GM, Flatmark K.

ESMO Open. 2017 May 2;2(2):e000158. doi: 10.1136/esmoopen-2017-000158. eCollection 2017.

12.

Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival.

Bakke KM, Hole KH, Dueland S, Grøholt KK, Flatmark K, Ree AH, Seierstad T, Redalen KR.

Acta Oncol. 2017 Jun;56(6):813-818. doi: 10.1080/0284186X.2017.1287951. Epub 2017 Feb 17.

PMID:
28464745
13.

Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial.

Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Olsen KH, Giercksky KE, Julsrud L, Fodstad Ø, Dueland S, Flatmark K.

Ann Surg Oncol. 2017 Jul;24(7):1916-1922. doi: 10.1245/s10434-017-5814-6. Epub 2017 Feb 21.

PMID:
28224367
14.

Resection of synchronous liver metastases between radiotherapy and definitive surgery for locally advanced rectal cancer: short-term surgical outcomes, overall survival and recurrence-free survival.

Labori KJ, Guren MG, Brudvik KW, Røsok BI, Waage A, Nesbakken A, Larsen S, Dueland S, Edwin B, Bjørnbeth BA.

Colorectal Dis. 2017 Aug;19(8):731-738. doi: 10.1111/codi.13622.

PMID:
28181384
15.

Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells.

Kyte JA, Aamdal S, Dueland S, Sæbøe-Larsen S, Inderberg EM, Madsbu UE, Skovlund E, Gaudernack G, Kvalheim G.

Oncoimmunology. 2016 Oct 18;5(11):e1232237. doi: 10.1080/2162402X.2016.1232237. eCollection 2016.

16.

Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.

Van Laethem JL, Riess H, Jassem J, Haas M, Martens UM, Weekes C, Peeters M, Ross P, Bridgewater J, Melichar B, Cascinu S, Saramak P, Michl P, Van Brummelen D, Zaniboni A, Schmiegel W, Dueland S, Giurescu M, Garosi VL, Roth K, Schulz A, Seidel H, Rajagopalan P, Teufel M, Childs BH.

Target Oncol. 2017 Feb;12(1):97-109. doi: 10.1007/s11523-016-0469-y.

PMID:
27975152
17.

Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy.

Kalanxhi E, Risberg K, Barua IS, Dueland S, Waagene S, Andersen SN, Pettersen SJ, Lindvall JM, Redalen KR, Flatmark K, Ree AH.

Cancer Res Treat. 2017 Apr;49(2):374-386. doi: 10.4143/crt.2016.080. Epub 2016 Jul 28.

18.

Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening.

Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH.

BMC Cancer. 2016 Jul 26;16:536. doi: 10.1186/s12885-016-2601-x.

19.

Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort.

Frøysnes IS, Larsen SG, Spasojevic M, Dueland S, Flatmark K.

J Surg Oncol. 2016 Aug;114(2):222-7. doi: 10.1002/jso.24290. Epub 2016 May 12.

PMID:
27173150
20.

Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer.

Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH.

Oncotarget. 2016 Jun 7;7(23):34907-17. doi: 10.18632/oncotarget.8995.

21.

Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?

Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH.

Radiother Oncol. 2016 Jun;119(3):505-11. doi: 10.1016/j.radonc.2016.02.020. Epub 2016 Mar 8.

PMID:
26968754
22.

Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome.

Dueland S, Ree AH, Grøholt KK, Saelen MG, Folkvord S, Hole KH, Seierstad T, Larsen SG, Giercksky KE, Wiig JN, Boye K, Flatmark K.

Clin Oncol (R Coll Radiol). 2016 Aug;28(8):532-9. doi: 10.1016/j.clon.2016.01.014. Epub 2016 Feb 14.

PMID:
26888115
23.

High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer.

Redalen KR, Sitter B, Bathen TF, Grøholt KK, Hole KH, Dueland S, Flatmark K, Ree AH, Seierstad T.

Radiother Oncol. 2016 Feb;118(2):393-8. doi: 10.1016/j.radonc.2015.11.031. Epub 2015 Dec 17.

24.

Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin.

Andersson Y, Engebraaten O, Juell S, Aamdal S, Brunsvig P, Fodstad Ø, Dueland S.

Br J Cancer. 2015 Dec 1;113(11):1548-55. doi: 10.1038/bjc.2015.380. Epub 2015 Nov 10.

25.

A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours.

Venugopal B, Awada A, Evans TR, Dueland S, Hendlisz A, Rasch W, Hernes K, Hagen S, Aamdal S.

Cancer Chemother Pharmacol. 2015 Oct;76(4):785-92. doi: 10.1007/s00280-015-2846-0. Epub 2015 Aug 20.

PMID:
26289594
26.

Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.

Labori KJ, Katz MH, Tzeng CW, Bjørnbeth BA, Cvancarova M, Edwin B, Kure EH, Eide TJ, Dueland S, Buanes T, Gladhaug IP.

Acta Oncol. 2016;55(3):265-77. doi: 10.3109/0284186X.2015.1068445. Epub 2015 Jul 25.

PMID:
26213211
27.

Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer.

Hektoen HH, Flatmark K, Andersson Y, Dueland S, Redalen KR, Ree AH.

BMC Cancer. 2015 Jul 24;15:543. doi: 10.1186/s12885-015-1557-6.

28.

MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer.

Seierstad T, Hole KH, Grøholt KK, Dueland S, Ree AH, Flatmark K, Redalen KR.

Br J Radiol. 2015 Jul;88(1051):20150097. doi: 10.1259/bjr.20150097. Epub 2015 Apr 22.

29.

Transarterial Chemoembolization of Liver Metastases from Uveal Melanoma Using Irinotecan-Loaded Beads: Treatment Response and Complications.

Carling U, Dorenberg EJ, Haugvik SP, Eide NA, Berntzen DT, Edwin B, Dueland S, Røsok B.

Cardiovasc Intervent Radiol. 2015 Dec;38(6):1532-41. doi: 10.1007/s00270-015-1093-4. Epub 2015 Apr 2.

PMID:
25832764
30.

A Novel Concept for Partial Liver Transplantation in Nonresectable Colorectal Liver Metastases: The RAPID Concept.

Line PD, Hagness M, Berstad AE, Foss A, Dueland S.

Ann Surg. 2015 Jul;262(1):e5-9. doi: 10.1097/SLA.0000000000001165.

PMID:
25692361
31.

Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapies.

Ree AH, Flatmark K, Saelen MG, Folkvord S, Dueland S, Geisler J, Redalen KR.

Crit Rev Oncol Hematol. 2015 Jul;95(1):114-24. doi: 10.1016/j.critrevonc.2015.01.003. Epub 2015 Jan 12.

PMID:
25624177
32.

Reirradiation of locally recurrent rectal cancer: a systematic review.

Guren MG, Undseth C, Rekstad BL, Brændengen M, Dueland S, Spindler KL, Glynne-Jones R, Tveit KM.

Radiother Oncol. 2014 Nov;113(2):151-7. doi: 10.1016/j.radonc.2014.11.021. Epub 2014 Nov 26. Review.

33.

Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks.

Ree AH, Meltzer S, Flatmark K, Dueland S, Kalanxhi E.

Int J Mol Sci. 2014 Dec 9;15(12):22835-56. doi: 10.3390/ijms151222835. Review.

34.

[High-dose-rate brachytherapy in recurrent rectal cancer after conventional recurrence treatment].

Raabe NK, Sundfør K, Hole KH, Djupvik LH, Larsen SG, Dueland S.

Tidsskr Nor Laegeforen. 2014 Oct 28;134(20):1929-30. doi: 10.4045/tidsskr.14.1162. eCollection 2014 Oct 28. Norwegian. No abstract available.

35.

Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy?

Dueland S, Hagness M, Line PD, Guren TK, Tveit KM, Foss A.

Ann Surg Oncol. 2015 Jul;22(7):2195-200. doi: 10.1245/s10434-014-4137-0. Epub 2014 Oct 9.

PMID:
25297902
36.

Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer?

Dueland S, Guren TK, Hagness M, Glimelius B, Line PD, Pfeiffer P, Foss A, Tveit KM.

Ann Surg. 2015 May;261(5):956-60. doi: 10.1097/SLA.0000000000000786.

PMID:
24950280
37.

Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy.

Ree AH, Saelen MG, Kalanxhi E, Østensen IH, Schee K, Røe K, Abrahamsen TW, Dueland S, Flatmark K.

PLoS One. 2014 Feb 25;9(2):e89750. doi: 10.1371/journal.pone.0089750. eCollection 2014.

38.

Patterns of recurrence after liver transplantation for nonresectable liver metastases from colorectal cancer.

Hagness M, Foss A, Egge TS, Dueland S.

Ann Surg Oncol. 2014 Apr;21(4):1323-9. doi: 10.1245/s10434-013-3449-9. Epub 2013 Dec 27.

39.

Liver transplantation for nonresectable liver metastases from colorectal cancer.

Hagness M, Foss A, Line PD, Scholz T, Jørgensen PF, Fosby B, Boberg KM, Mathisen O, Gladhaug IP, Egge TS, Solberg S, Hausken J, Dueland S.

Ann Surg. 2013 May;257(5):800-6. doi: 10.1097/SLA.0b013e3182823957.

PMID:
23360920
40.

Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer.

Ree AH, Kristensen AT, Saelen MG, de Wijn R, Edvardsen H, Jovanovic J, Abrahamsen TW, Dueland S, Flatmark K.

PLoS One. 2012;7(11):e50806. doi: 10.1371/journal.pone.0050806. Epub 2012 Nov 30.

41.

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.

Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U.

Ann Oncol. 2013 Jan;24(1):152-60. doi: 10.1093/annonc/mds276. Epub 2012 Sep 11.

PMID:
22967994
42.

Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei.

Sørensen O, Flatmark K, Reed W, Wiig JN, Dueland S, Giercksky KE, Larsen SG.

Eur J Surg Oncol. 2012 Oct;38(10):969-76. doi: 10.1016/j.ejso.2012.06.552. Epub 2012 Jul 3.

PMID:
22763244
43.

Quality of life following liver transplantation in patients with liver metastases from colorectal carcinoma.

Andersen MH, Dueland S, Hagness M, Vidnes T, Finstad ED, Wahl AK, Foss A.

Scand J Caring Sci. 2012 Dec;26(4):713-9. doi: 10.1111/j.1471-6712.2012.00984.x. Epub 2012 Mar 27.

PMID:
22452269
44.

Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients.

Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S.

Clin Cancer Res. 2011 Jul 1;17(13):4568-80. doi: 10.1158/1078-0432.CCR-11-0184. Epub 2011 May 17.

45.

Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy.

Bratland A, Dueland S, Hollywood D, Flatmark K, Ree AH.

Radiat Oncol. 2011 Apr 8;6:33. doi: 10.1186/1748-717X-6-33.

46.

hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes.

Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G, Gaudernack G.

Cancer Immunol Immunother. 2011 Jun;60(6):809-18. doi: 10.1007/s00262-011-0991-9. Epub 2011 Mar 2.

47.

Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling.

Folkvord S, Flatmark K, Dueland S, de Wijn R, Grøholt KK, Hole KH, Nesland JM, Ruijtenbeek R, Boender PJ, Johansen M, Giercksky KE, Ree AH.

Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):555-62. doi: 10.1016/j.ijrobp.2010.04.036. Epub 2010 Aug 2.

PMID:
20675069
48.

Liver transplantation for colorectal liver metastases: revisiting the concept.

Foss A, Adam R, Dueland S.

Transpl Int. 2010 Jul;23(7):679-85. doi: 10.1111/j.1432-2277.2010.01097.x. Epub 2010 Apr 30.

49.

Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.

Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K.

Lancet Oncol. 2010 May;11(5):459-64. doi: 10.1016/S1470-2045(10)70058-9. Epub 2010 Apr 6.

PMID:
20378407
50.

Salvage surgery for locally recurrent rectal cancer: total mesorectal excision during the primary operation does not influence the outcome.

Wiig JN, Larsen SG, Dueland S, Flatmark K, Giercksky KE.

Colorectal Dis. 2011 May;13(5):506-11. doi: 10.1111/j.1463-1318.2010.02256.x.

PMID:
20236148

Supplemental Content

Loading ...
Support Center